A randomized, phase III trial exploring the effects of neoadjuvant sequential treatment with steroidal (exemestane) and non-steroidal (anastrozole) aromatase inhibitors on biomarkers in post-menopausal women with hormone receptor positive locally advanced breast cancer (LABC)

被引：0
|
作者：
Freedman, O. [1 ]
Amir, E. [1 ]
Dranitsaris, G. [1 ]
Dowsett, M. [2 ]
Cole, D. E. C. [3 ]
Hanna, W. [4 ]
O'Malley, F. [5 ]
Folkerd, E. [2 ]
Verma, S. [4 ]
Clemons, M. J. [1 ]
机构：
[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[2] Royal Marsden Hosp, London SW3 6JJ, England
[3] Univ Toronto, Lab Med & Pathobiol, Toronto, ON, Canada
[4] Odette Canc Ctr, Toronto, ON, Canada
[5] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)70919-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：269 / 269
页数：1
相关论文
共 50 条
  • [31] Oral vinorelbine (NVBo) and anastrozole (A) as neoadjuvant treatment of locally advanced (LA) breast cancer (BC) in hormone receptor positive (HR plus ) postmenopausal patients: Results of an international phase II trial
    Riggi, M.
    Moreno-Lopez, E. M.
    Rolski, J.
    Petruzelka, P.
    Ferrero, J. M.
    Tellez-Bernal, E.
    Vaissiere, N.
    Lucas, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial
    Wang, Changjun
    Lin, Yan
    Zhou, Yidong
    Mao, Feng
    Zhu, Hanjiang
    Guan, Jinghong
    Zhang, Xiaohui
    Shen, Songjie
    Huang, Xin
    Chen, Chang
    Yao, Ru
    Zhao, Jialin
    Sun, Qiang
    BMC CANCER, 2020, 20 (01)
  • [33] Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial
    Changjun Wang
    Yan Lin
    Yidong Zhou
    Feng Mao
    Hanjiang Zhu
    Jinghong Guan
    Xiaohui Zhang
    Songjie Shen
    Xin Huang
    Chang Chen
    Ru Yao
    Jialin Zhao
    Qiang Sun
    BMC Cancer, 20
  • [34] Ribociclib (RIB) plus non-steroidal aromatase inhibitor (NSAI) plus goserelin in premenopausal Asian women with hormone-receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from the randomized phase III MONALEESA-7 study
    Im, S-A.
    Sohn, J.
    Tripathy, D.
    Chow, L.
    Lee, K. S.
    Jung, K. H.
    Babu, G.
    Im, Y-H.
    El Saghir, N.
    Liu, M-C.
    Diaz-Padilla, I.
    Alam, J.
    Kong, O.
    Miller, M.
    Lu, Y-S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [35] Gruppo Italiano Mammella (GIM) 10-CONSENT: A phase III randomized study comparing concurrent versus sequential administration of adjuvant chemotherapy (CT) and aromatase inhibitors (AIs) in post-menopausal patients (pts) with hormone receptor-positive (HR plus ) early breast cancer (EBC)
    Lambertini, M.
    Guarneri, V.
    Caremoli, E. R.
    Rocca, A.
    Montemurro, F.
    De laurentiis, M.
    Giordano, M.
    De Placido, S.
    Bisagni, G.
    Garrone, O.
    Ferzi, A.
    Giovanardi, F.
    Cognetti, F.
    Amaducci, L.
    Bernardo, A.
    Livi, L.
    Bighin, C.
    Poggio, F.
    Ballestrero, A.
    Del Mastro, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S47 - S47
  • [36] PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) resistant to aromatase inhibitor (AI) therapy
    Kornblum, N. S.
    Manola, J.
    Klein, P.
    Ramaswamy, B.
    Brufsky, A.
    Stella, P. J.
    Burnette, B.
    Telli, M.
    Makower, D. F.
    Leach, J.
    Truica, C. I.
    Wolff, A. C.
    Soori, G. S.
    Haley, B.
    Nagarajan, A.
    Wassenaar, T. R.
    Goldstein, L.
    Miller, K. D.
    Sparano, J. A.
    CANCER RESEARCH, 2017, 77
  • [37] Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials
    Ramos-Esquivel, Allan
    Hernandez-Steller, Hellen
    Savard, Marie-France
    Ulises Landaverde, Denis
    BREAST CANCER, 2018, 25 (04) : 479 - 488
  • [38] Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials
    Allan Ramos-Esquivel
    Hellen Hernández-Steller
    Marie-France Savard
    Denis Ulises Landaverde
    Breast Cancer, 2018, 25 : 479 - 488
  • [39] Phase III study of Palbociclib in combination with Exemestane vs. Capecitabine, in Hormonal Receptor (HR) positive/HER2 negative Metastatic Breast Cancer (MBC) patients with Resistance to non-steroidal Aromatase inhibitors (NSAI): PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006)
    Martin, Miguel
    Inbar, Moshe J.
    Maria Carrasco, Eva
    Lang, Istvan
    Jose Escudero, Maria
    Kahan, Zsuzsanna
    Huang Bartlett, Cynthia
    Bermejo, Begona
    Gal Yam, Einav
    Ignacio Chacon, Jose
    Zvirbule, Zanete
    Garcia Saenz, Jose Angel
    de la Haba-Rodriguez, Juan
    Koehler, Maria
    Gil Gil, Miguel J.
    Ciruelos Gil, Eva Maria
    Munoz-Mateu, Montserrat
    Morales Murillo, Serafin
    Luis Alonso, Jose
    Zielinski, Christoph
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [40] Phase III study of palbociclib in combination with exemestane vs. capecitabine, in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with resistance to non-steroidal aromatase inhibitors (NSAI): PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006)
    Martin, Miguel
    Beslija, Semir
    Carrasco, Eva
    Kahan, Zsuzanna
    Jose Escudero, Ma
    Lang, Istvan
    Bermejo, Begona
    Inbar, Moshe
    Ignacio Chacon, Jose
    Jinga, Dan
    Angel Garcia-Saenz, Jose
    de la Haba, Juan
    Morales, Serafin
    Gil, Miguel
    Murillo, Laura
    Anton, Antonio
    Ruiz-Borrego, Manuel
    Zielinski, Christoph
    Steger, Guenther
    Nisenbaum, Bella
    CANCER RESEARCH, 2015, 75
12345